Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
This randomized phase II trial studies how well temozolomide and capecitabine work compared
to standard treatment with cisplatin or carboplatin and etoposide in treating patients with
neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other
parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy,
such as temozolomide, capecitabine, cisplatin, carboplatin and etoposide, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Certain types of neuroendocrine carcinomas may
respond better to treatments other than the current standard treatment of cisplatin and
etoposide. It is not yet known whether temozolomide and capecitabine may work better than
cisplatin or carboplatin and etoposide in treating patients with this type of neuroendocrine
carcinoma, called non-small cell neuroendocrine carcinoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.